Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIBIA Neurosciences (SIBI) -- Ignore unavailable to you. Want to Upgrade?

To: Larry Liebman who wrote (200)	7/23/1998 2:46:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 579

Using NXCO as a corner stone is good practice. It's one that John Metcalf set, immediately after the deal. I have never seen research premiums discounted to this degree. This, restricting your analysis to quality second- and third-tiers, makes December '94 look like a paltry event. The sector has reinvented itself. This is not clear to most investors. They think of biotech as the LIPOs of the world. For several years, biotech has turned to biological molecules as indicators, the intent being to "outpharm the pharmas". The sector has reinvented itself.